Efficacy and safety of Fuzheng Huayu tablet on persistent advanced liver fibrosis following 2 years entecavir treatment: A single arm clinical objective performance criteria trial-Reference-Cited by-同舟云学术

Efficacy and safety of Fuzheng Huayu tablet on persistent advanced liver fibrosis following 2 years entecavir treatment: A single arm clinical objective performance criteria trial

Published:2022-11 Issue: Volume:298 Page:115599
ISSN:0378-8741
Container-title:Journal of Ethnopharmacology
language:en
Short-container-title:Journal of Ethnopharmacology

Author:

Zhao Zhi-Min,Zhu Chuan-Wu,Huang Jia-Quan,Li Xiao-Dong,Zhang Yu-Xi,Liang Jian,Zhang Wei,Zhang Yong,Jiang Xian-Gao,Zong Ya-Li,Zhang Ke-Jun,Sun Ke-Wei,Zhang Biao,Lv Yun-Hai,Xing Hui-Chun^ORCID,Xie Qing,Liu Ping,Liu Cheng-Hai^ORCID

Publisher

Elsevier BV

Subject

Drug Discovery,Pharmacology

Reference30 articles.

1. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B;Chang;N. Engl. J. Med.,2006

2. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B;Chang;Hepatology,2010

3. Safety and therapeutic effects of anti-fibrotic Traditional Chinese Medicine Fuzheng Huayu on persistent advanced stage fibrosis following 2 years entecavir treatment: study protocol for a single arm clinical objective performance criteria trial;Chen;Contemp. Clin Trials Commun.,2020

4. Common views on diagnosis and treatment of liver fibrosis in integrated traditional and western medicine (2017 update);Committee;Clin. J. Integr. Trad. West Med. Dig.,2017

5. Hepatocytes as immunological agents;Crispe;J. Immunol.,2016

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic Effects of Qingchang Tongluo Decoction on Intestinal Fibrosis in Crohn’s Disease: Network Pharmacology, Molecular Docking and Experiment Validation;Drug Design, Development and Therapy;2024-07

2. Progress in clinical and basic research of fuzheng Huayu formula for the treatment of liver fibrosis;Journal of Ethnopharmacology;2024-06

3. Hepatitis B: Model Systems and Therapeutic Approaches;Journal of Immunology Research;2024-05-07

4. Tianhuang formula ameliorates liver fibrosis by inhibiting CCL2-CCR2 axis and MAPK/NF-κB signaling pathway;Journal of Ethnopharmacology;2024-03

5. Recent progress on the application of compound formulas of traditional Chinese medicine in clinical trials and basic research in vivo for chronic liver disease;Journal of Ethnopharmacology;2024-03